[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344931-105":59,"doc-detail-344931-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-age-of-molecular-biomarkers-cancer-in-the-era-of-personalized-medicine-review-what-do-pathologists-in-developing-countries-need-to-know-and-understand","The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine - Review - What Do Pathologists in Developing Countries Need to Know and Understand?","","Cancer care complexity is accelerating in the era of personalized medicine, shifting diagnosis and management toward precision oncology. The review explains how advanced molecular testing identifies tumor molecular characteristics to guide targeted, prognostic and predictive biomarker–driven therapies. It covers tumor-agnostic treatment concepts, including shared genomic alterations across cancer types, and highlights the need for pathologists to adapt. Emphasis is placed on resource-limited settings, next-generation sequencing, comprehensive genomic profiling, liquid biopsy, and understanding tumor heterogeneity and resistance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-age-of-molecular-biomarkers-cancer-in-the-era-of-personalized-medicine-review-what-do-pathologists-in-developing-countries-need-to-know-and-understand/344931/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-age-of-molecular-biomarkers-cancer-in-the-era-of-personalized-medicine-review-what-do-pathologists-in-developing-countries-need-to-know-and-understand/344931.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main goal of precision oncology described in the review?","Question",{"text":113,"@type":114},"To identify cancer patients who are candidates for specific targeted therapies based on the molecular characteristics of malignant tumors identified through advanced molecular testing.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do tumor-agnostic therapies work according to the review?",{"text":118,"@type":114},"They can treat different cancer types across multiple organs when they share the same molecular alterations or genomic alterations.",{"name":120,"@type":111,"acceptedAnswer":121},"Which new technologies are highlighted as important for pathologists to understand?",{"text":122,"@type":114},"Next Generation Sequencing and Comprehensive Genomic Profiling, along with liquid biopsies and DNA and transcriptome studies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344931,1790216164,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","International Journal of General Medicine  \n Open Access Full Text Article  \nREVIEW  \nThe Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine. What Do Pathologists in Developing Countries Need to Know and Understand?  \nZubair Ahmad 1 , Shabina Rahim2 , Maha Zubair 3 , Jamshid Abdul-Ghafar 4  \n1Department of Pathology, Sultan Qaboos Comprehensive Cancer Care and Research Centre, Muscat, Oman; 2Pathology Department, Royal Medical Services, Military Hospital, Manama, Bahrain; 3Department of Internal Medicine, LSU Health Shreveport, Shreveport, LA, USA; 4Department of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children (FMIC), Kabul, Afghanistan  \nCorrespondence: Jamshid Abdul-Ghafar, Department of Pathology and Clinical Laboratory, French Medical Institute for Mother and Children (FMIC), Kabul, Afghanistan, Email [jamshid.jalal@fmic.org.af](jamshid.jalal@fmic.org.af)  \n\n| Abstract: The complexity of cancer care is continuously increasing in the era of personalized medicine and there is a paradigm shift in the diagnosis and management of cancer. This is the era of precision oncology whose main objective is to identify cancer patients who are candidates for specific targeted therapies. This advanced approach to cancer care formulates treatment strategies for cancer patients based on the specific molecular characteristics of a malignant tumor which are identified through advanced molecular testing. This is the age of advanced prognostic and predictive biomarkers. Targeted therapies represent a groundbreaking shift in cancer therapy and are the cornerstone of precision oncology. Termed “tumor agnostic therapy”, these drugs can treat different cancer types across multiple organs which demonstrate the same molecular alterations. A targeted drug in a specific cancer may be effective in another non-related cancer if the same genomic alteration is present. Pathologists need to appreciate these radical and exciting changes and adapt their practices as they will be required to be collaborative clinicians in the new era with a role in diagnosis, prognostication, and treatment of cancer. Pathologists need to become familiar with the ever-expanding number of new biomarkers and their crucial role in cancer care. They need to understand and adapt to new technologies such as Next Generation Sequencing and Comprehensive Genomic Profiling, liquid biopsies, DNA and transcriptome studies etc. They also need to familiarize themselves with tumor agnostic therapies, and concepts such as tumor heterogeneity and resistance to therapy. They can no longer be just morphologists but assume a central role in cancer care. Pathologists in developing countries and resource limited settings who may not currently have access to advanced molecular techniques need to be aware of and understand these fundamental shifts in cancer care and especially their role in the new era. The major changes in cancer care in the era of personalized medicine are discussed in this review mainly for the benefit of pathologists working in LMICs.\u003Cbr>Keywords: cancer, pathologists, developing countries |\n| --- |\n| Introduction\u003Cbr>The classical approach to cancer is undergoing a paradigm shift. We are witnessing a radical change in the diagnosis, prognostication and management of cancer. The complexity of cancer care is continuously increasing in the new era of“precision medicine” or “molecular guided medicine”. This change is happening owing to two of the most impressive technical advances in recent history. One is the remarkable development of DNA and protein detecting technologies that can detect a variety of minute and precise changes at the molecular level in enormous numbers at ever increasing speed. These include DNA sequencing, microarray technologies, comparative genomic hybridization, digital PCR, mass spectrometry and others, and each generates data in enormous and unprecedented amounts – “big data”. The other is the tremendou","cbCait257xChZsSm","https://ap.wps.com/l/cbCait257xChZsSm","pdf",733308,35,"English","# Introduction\n# Molecular technologies and “big data” enabling precision oncology\n# Targeted therapies and tumor-agnostic treatment\n# Biomarkers for prognosis and treatment prediction\n# Implications for pathologists in developing countries\n# Adapting practice: new tools and concepts","[{\"question\":\"What is the main goal of precision oncology described in the review?\",\"answer\":\"To identify cancer patients who are candidates for specific targeted therapies based on the molecular characteristics of malignant tumors identified through advanced molecular testing.\"},{\"question\":\"How do tumor-agnostic therapies work according to the review?\",\"answer\":\"They can treat different cancer types across multiple organs when they share the same molecular alterations or genomic alterations.\"},{\"question\":\"Which new technologies are highlighted as important for pathologists to understand?\",\"answer\":\"Next Generation Sequencing and Comprehensive Genomic Profiling, along with liquid biopsies and DNA and transcriptome studies.\"}]","The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine - Review - What Do Pathologists in Developing Countries Need to Know and Understand? | PDF",1790055817,88,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/850e01e0c54640d32a287a0b12a5d64d.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9cc6dec1da102d4ae711bf11d6c43aa.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ccad41973d6c63b3031ef33df8d2d58.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c6860f3f7752c2ea6ff00ce9d827eb6.webp",980,1268]